ANEB - NASDAQ

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%

HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$70.67M

EPS-0.2500

P/E Ratio-5.74

Earnings Date02/12/2026

aneb

Research Development Expenses

Last Annual Value

4.30M

3-Year CAGR

13%

5-Year CAGR

96%

10-Year CAGR

40%

Adjust for Inflation

Anebulo Pharmaceuticals, Inc. Competitors Analysis of research-development-expenses

ANEB · NASDAQ

Company	research-development-expenses	CAGR 3Y	CAGR 5Y	CAGR 10Y
Anebulo Pharmaceuticals, Inc. NASDAQ:ANEB	4.30M	-8.4%	13.6%	N/A
Clene Inc. NASDAQ:CLNN	14.01M	-19.3%	-13.2%	N/A
Immix Biopharma, Inc. NASDAQ:IMMX	16.26M	23.0%	164.1%	N/A
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL	107.30M	-23.0%	-9.4%	N/A
aTyr Pharma, Inc. NASDAQ:ATYR	60.22M	12.5%	21.0%	3.1%
Biomea Fusion, Inc. NASDAQ:BMEA	61.98M	-15.5%	17.2%	N/A
eXoZymes, Inc. NASDAQ:EXOZ	3.71M	91.5%	52.2%	N/A
Fractyl Health, Inc. Common Stock NASDAQ:GUTS	74.54M	25.1%	23.0%	N/A
Oramed Pharmaceuticals Inc. NASDAQ:ORMP	6.38M	-10.7%	-21.2%	-1.9%
Quince Therapeutics, Inc. NASDAQ:QNCX	18.59M	25.3%	-21.1%	N/A
Spruce Biosciences, Inc. NASDAQ:SPRB	19.52M	-26.6%	-8.7%	N/A

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.72

Related Guides

Blog Categories

Continue your ANEB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.